Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-17T09:18:27.320Z Has data issue: false hasContentIssue false

Management of physical health in patients with schizophrenia: international insights

Published online by Cambridge University Press:  16 April 2020

I.B. Chaudhry*
Affiliation:
Lancashire Care NHS Trust Early Intervention Service, The Mount, Whalley Road, Accrington, BB5 5DE, United-Kingdom
J. Jordan
Affiliation:
Medical School Hannover, Carl-Neuberg-Str. 1, 30625Hannover, Germany
F.-R. Cousin
Affiliation:
Chi Poissy Saint Germain En Laye, 20 rue Armagis, 78105 St Germain en Laye cedex
R. Cavallaro
Affiliation:
Clinica Psichiatrica Università di Milano, Ospedale San Raffaele, Via Stamira D’Ancona, 20
J.M. Mostaza
Affiliation:
Unidad de Arteriosclerosis, Hospital Carlos III, Sinesio Delgado, 10, 28029Madrid, Spain
*
Correspondence. Tel.: +44 (0)1254 226392. E-mail address: ibchaudhry@btinternet.com
Get access

Abstract

This international meeting discussed the management of physical health in patients with schizophrenia in several countries including France, Spain, Germany, the UK and Italy. Physical health parameters, including weight, blood pressure, blood glucose, lipids and standard biochemical assessments are measured in many patients at the first hospital consultation. These reveal physical disorders such as obesity, hypertension, dyslipidaemia, the metabolic syndrome, substance abuse, cardiovascular disease, extrapyramidal symptoms, sexual dysfunction and diabetes in substantial proportions of patients. Psychiatrists consider switching antipsychotic therapy if excessive sedation, extrapyramidal symptoms, unacceptable weight gain, hyperglycaemia or dyslipidaemia occur. In general, switching is more likely to be considered for symptomatic adverse events than for laboratory abnormalities. Switching is discouraged by limited knowledge of protocols, the absence of guidelines and fears of relapse or reduced treatment adherence. The physical health of patients with schizophrenia receives much less attention in the community setting than in the hospital setting. Improved guidelines, protocols, resources and support are needed to improve the physical health of patients in the community.

Type
Research Article
Copyright
Copyright © 2010 Elsevier Masson SAS

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evalutaion, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486–97.CrossRefGoogle Scholar
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596601CrossRefGoogle Scholar
Barnett, A.H.Mackin, P.Chaudhry, I.Farooqi, A.Gadsby, R.Heald, A., et al.Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007; 21: 357373CrossRefGoogle ScholarPubMed
Bodenheimer, T.Wagner, E.H.Grumbach, K.Improving primary care for patients with chronic illness. JAMA 2002; 288: 17751779CrossRefGoogle ScholarPubMed
National Collaborating Centre for Mental Health. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). 2009. National Institute for Health and Clinical Excellence, London, UK. Last accessed 6 August 2009. http://www.guideline.gov/summary/summary.aspx?doc_id=14313.Google Scholar
Submit a response

Comments

No Comments have been published for this article.